Standard BioTools Inc
Company Profile
Business description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Contact
50 Milk Street
10th Floor
BostonMA02109
USAT: +1 650 266-6000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
389
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,983.22 | 96.26 | 1.22% |
| DAX 40 | 26,062.68 | 358.66 | 1.40% |
| Dow JONES (US) | 52,360.95 | 114.15 | -0.22% |
| FTSE 100 | 10,734.35 | 39.85 | 0.37% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,199.56 | 350.29 | -1.32% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,718.37 | 25.61 | -0.33% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |